Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$3.39 USD
-0.20 (-5.57%)
Updated May 17, 2024 04:00 PM ET
After-Market: $3.39 0.00 (0.00%) 6:22 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRBU 3.39 -0.20(-5.57%)
Will CRBU be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CRBU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBU
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy
CRBU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe Caribou Biosciences, Inc. (CRBU) Could Rally 285.29%: Here's is How to Trade
Does Caribou Biosciences, Inc. (CRBU) Have the Potential to Rally 321.46% as Wall Street Analysts Expect?
Other News for CRBU
Analysts Conflicted on These Healthcare Names: AstraZeneca (GB:AZN), Sartorius (GB:0NIR) and Caribou Biosciences (CRBU)
Truist Financial Releases a Buy Rating on Caribou Biosciences (CRBU)
Attention Biotech Investors - Stocks To Watch
Expert Ratings For Caribou Biosciences
Caribou Biosciences (CRBU) Receives a Buy from Bank of America Securities